EUHASS: The European Haemophilia Safety Surveillance system.
about
The European Haemophilia Network (EUHANET)Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.The current state of adverse event reporting in hemophilia.The safety of pharmacologic options for the treatment of persons with hemophilia.A new recombinant factor VIII: from genetics to clinical use.Parvovirus transmission by blood products - a cause for concern?Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyInhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.New treatments in hemophilia: insights for the clinician.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Joint protection in haemophilia.Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.The modern treatment of haemophilia: a narrative reviewHaemophilia B: current pharmacotherapy and future directions.Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.Enhancing haemophilia care through registries.Joint WFH-ISTH session: issues in clinical trial design.The growing number of hemophilia registries: Quantity vs. quality.Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres.Safety surveillance in haemophilia and allied disorders.Advances in the treatment of bleeding disorders.Establishing a harmonized haemophilia registry for countries with developing health care systems.Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries.Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers.Issues in the ageing individual with haemophilia and other inherited bleeding disorders: understanding and responding to the patients' perspective.Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.Factor VIII inhibitor and source of replacement therapy.Managing haemophilia for life: 4th Haemophilia Global Summit.Concentrate-related inhibitor risk: is a difference always real?Rare congenital bleeding disorders
P2860
Q27001556-9D27B8A3-86D5-4112-A7FC-4E137EC5D377Q30234910-3F7CC913-50D7-43D2-9461-9A33BC437A88Q30239952-892274D9-2ECC-4DD4-BC4D-5978C78E5707Q30249200-AED7C901-FE7F-43E1-9281-0A9B536DC489Q30370282-6B858BC1-B059-4195-89A4-6138A94615A3Q30571511-C69A2313-A3FB-4530-A650-F3D02F30372BQ33709003-21E2ADD3-3551-41BB-8981-40072C4969F3Q34063824-E437B289-690F-4315-BED2-41AEF8F0954EQ34416394-6ABD0C2F-5203-4D04-993B-1340231B4BF7Q34784564-2182E806-A49F-438E-8D17-039F394865C6Q35209354-61D76506-9E5C-4AAC-94CF-FB0F27374BA7Q36612681-E6E15D34-5F30-4AE0-839D-AF033CFE2A6DQ37185097-E8DEE83C-0833-473F-8A29-5F008A19941BQ37912258-F8A74EFA-E146-42FD-9981-FBCB7AD178DCQ37984127-199AED7B-4461-4CA4-A14F-4C44CA02741AQ38025882-A4437E35-1707-4E4B-B0B4-9B25D47D20CEQ38040458-A7385E16-D14B-43BE-B6A6-9A4132607A69Q38188654-05956433-C0BE-4E00-9DF5-00411932AA59Q38206861-9907D7EC-8ACB-44AE-B1DA-9F6C893A7AF2Q38206863-CF64C6E9-7266-4608-917E-8A89DD0C6F33Q38351067-FC1BFA0D-AE36-49AD-844E-898171255A55Q38412212-2EDBCC4C-EA7C-4B97-B11E-27F81C6192FEQ38784133-701336D3-095C-4A30-B1EE-09AE6F7F6803Q38945123-C7FF51EE-DE4A-4E09-B58B-B9406D7ECF0FQ39434363-71A2D6C7-2870-4901-BCB3-A49AF14C5451Q41504794-8BA5B984-88E6-4DC3-991A-AC6B01E4EDBCQ41951538-56812085-B605-449D-AA56-26B1C26BDE84Q42244618-EDC6F733-480F-46F7-A24B-4AE2B9CCF091Q42923887-92B994B4-3DC3-468D-AAAA-2D10D6FCD176Q43056247-5F775416-6E15-45F6-B733-D0C89302732BQ44122887-ECC4D32B-27AB-462B-B5FB-6DB28746ADC2Q45872627-B895AFD4-B7E6-4925-8A2A-0635A5368F59Q57300570-4A2EEB42-5EF5-4855-A0C1-83A65AA79DDA
P2860
EUHASS: The European Haemophilia Safety Surveillance system.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
EUHASS: The European Haemophilia Safety Surveillance system.
@en
EUHASS: The European Haemophilia Safety Surveillance system.
@nl
type
label
EUHASS: The European Haemophilia Safety Surveillance system.
@en
EUHASS: The European Haemophilia Safety Surveillance system.
@nl
prefLabel
EUHASS: The European Haemophilia Safety Surveillance system.
@en
EUHASS: The European Haemophilia Safety Surveillance system.
@nl
P2093
P1433
P1476
EUHASS: The European Haemophilia Safety Surveillance system.
@en
P2093
C A Ludlam
E A Gilman
G Calizzani
P M Mannucci
P356
10.1016/S0049-3848(10)70150-X
P478
127 Suppl 2
P577
2011-01-01T00:00:00Z